Biotechnology company Genentech Inc. says sales of its cancer treatments, led by blockbuster drugs Avastin and Rituxan, drove nearly 5% growth in second-quarter profit, but the results did not meet Wall Street forecasts.
The South San Francisco, Calif.-based company Genentech Inc. (DNA) says its quarterly profit rose to $782 million, or 73 cents per share, from $747 million, or 70 cents per share, in the prior-year period. Revenue rose 8% to just under $3.24 billion from $3 billion.
Excluding 2 cents per share for acquisitions and special items, the company earned 75 cents per share in the latest quarter.
Analysts polled by Thomson Financial expected profit of 86 cents per share on revenue of $3.23 billion.
« Steelers look to restructure ownership – FBI probes IndyMac »
No comments yet.
Sorry, the comment form is closed at this time.
Powered by WordPress -- XHTML 1.0